Overview

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

Status:
Active, not recruiting

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

This phase I/II clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FMS-like tyrosine Kinase 3 (FLT3) mutation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Technische Universität Dresden

Collaborators:

Novartis Pharmaceuticals
Pfizer

Treatments:

Cytarabine
Daunorubicin
Gemtuzumab
Midostaurin
Staurosporine